Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Assertio Holdings, Inc.ASRT · Entity 37706 | Director | December 05, 2020 | December 07, 2020 |
| Assertio Therapeutics, IncASRT · Entity 149352 | Director · Director, President and CEO | February 12, 2020 | February 12, 2020 |
| ECOLAB INC.ECL · Entity 2954 | Director | March 31, 2025 | April 02, 2025 |
| ZIMMER BIOMET HOLDINGS, INC.ZBH · Entity 3278 | Director | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Assertio Holdings, Inc.
Report date December 05, 2020 · Filed December 07, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 564,239 |
Reported balance
After 2020-12-05 transaction · row 1
1 source rowRow 1 · 2020-12-05 · Exercise / conversion · Acquired 73,529 · Balance 564,239 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2020-12-05 | Direct | 0 |
Reported balance
After 2020-12-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-12-05 · Exercise / conversion · Disposed 73,529 · Balance 0 F1: Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock. F2: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 175,000 |
Reported balance
Holding disclosure · report date 2020-12-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 175,000 |
| Common StockSEC Table I · non-derivative | IndirectBy Child | 3,000 |
Reported balance
Holding disclosure · report date 2020-12-05 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 3,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock.
F2: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities.
Assertio Therapeutics, Inc
Report date February 12, 2020 · Filed February 12, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 244,739 |
Ending reported balance
After 2020-02-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-02-12 · Exercise / conversion · Acquired 97,412 · Balance 275,747 Row 2 · 2020-02-12 · Tax withholding · Disposed 31,008 · Balance 244,739 F1: Represents shares of common stock withheld for payment of taxes upon the vesting of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2022-02-12 | Direct | 194,825 |
Reported balance
After 2020-02-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-02-12 · Exercise / conversion · Disposed 97,412 · Balance 194,825 F2: Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock. F4: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. F3: One-third of these restricted stock units are scheduled to vest on each of February 12, 2020, 2021 and 2022. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 175,000 |
Reported balance
Holding disclosure · report date 2020-02-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 175,000 |
| Common StockSEC Table I · non-derivative | IndirectBy Child | 3,000 |
Reported balance
Holding disclosure · report date 2020-02-12 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 3,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock withheld for payment of taxes upon the vesting of restricted stock units.
F2: Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock.
F3: One-third of these restricted stock units are scheduled to vest on each of February 12, 2020, 2021 and 2022.
F4: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities.
ECOLAB INC.
Report date March 31, 2025 · Filed April 02, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,741.32 |
Reported balance
After 2025-03-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-03-31 · Grant · Acquired 134.16 · Balance 26,741.32 F1: Includes 72.09 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan. |
| Common StockSEC Table I · non-derivative | Direct | 26,865.54 |
Reported balance
After 2025-03-31 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-03-31 · Grant · Acquired 124.22 · Balance 26,865.54 |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 72.09 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan.
ZIMMER BIOMET HOLDINGS, INC.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $89.85 | Direct | 38,077.496 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 306.066 · Balance 38,077.496 F1: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F4: Includes 96.739 phantom stock units accrued on July 31, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
F2: The Conversion or Exercise Price of Derivative Security is 1-for-1.
F3: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs.
F4: Includes 96.739 phantom stock units accrued on July 31, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 01, 2020 Filed Dec 2, 2020 21:58 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | Exercise / conversionCommon Stock | 34,860 | $0.00 | $0.00 |
DisclosureSEC source: 0001808665-20-000060 · wf-form4_160694631758789.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 490,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 20:43 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 137.6 | $199.86 | $27,500.05 |
DisclosureSEC source: 0001179110-20-010180 · edgar.xml · nonDerivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,140.34 F1 · balance_after: Includes 44.41 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 20:43 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 143.85 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-010180 · edgar.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,958.33 Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 20:37 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 239.393 | $0.00 Strike: $135.76 | $0.00 |
DisclosureSEC source: 0001062993-20-004778 · form4.xml · derivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,655.122 Underlying: Common Stock · 239.393 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F3 · derivative.expiration_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F4 · balance_after: Includes 44.452 phantom stock units accrued on July 31, 2020 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:48 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 126.75 | $197.24 | $25,000.17 |
DisclosureSEC source: 0001179110-20-007959 · edgar.xml · nonDerivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,814.48 F1 · balance_after: Includes 51.04 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:48 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 133.09 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-007959 · edgar.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,636.69 Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:54 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 274.54 | $0.00 Strike: $118.38 | $0.00 |
DisclosureSEC source: 0000911916-20-000161 · edgar.xml · derivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,371.277 Underlying: Common Stock · 274.54 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F3 · derivative.expiration_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 21:16 UTC | ECOLAB INC. ECL · Entity 2954 | Exercise / conversionNon-Employee Director Stock Option (Right to Buy) · Derivative | 3,800 | $0.00 Strike: $64.00 | $0.00 |
DisclosureSEC source: 0001179110-20-006926 · edgar.xml · derivative · entry 3 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,800 shares Expires 2022-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option became exercisable, on a cumulative basis, as to 25% of the option shares (excluding any fractional portion less than one share), on the last day of each of the first, second and third three-month periods following its date of grant and as to the remaining shares on the last day of the fourth three-month period following its date of grant. The date listed in the "Date Exercisable" column represents the first vesting date. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 21:16 UTC | ECOLAB INC. ECL · Entity 2954 | SaleCommon Stock | 3,800 | $212.28 | $806,645.00 |
DisclosureSEC source: 0001179110-20-006926 · edgar.xml · nonDerivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,503.6 Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 21:16 UTC | ECOLAB INC. ECL · Entity 2954 | Exercise / conversionCommon Stock | 3,800 | $64.00 | $243,181.00 |
DisclosureSEC source: 0001179110-20-006926 · edgar.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,303.6 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2020 Filed May 23, 2020 00:39 UTC | Assertio Holdings, Inc. ASRT · Entity 37706 | GrantCommon Stock | 211,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001808665-20-000021 · wf-form4_159019434477299.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 455,850 F1 · date: As a result of a holding company reorganization effective May 19, 2020, Assertio Holdings, Inc., is the successor issuer to Assertio Therapeutics, Inc., pursuant to 12g-3(a) of the Exchange Act. F2 · shares: Restricted stock units that vest in full on the first anniversary of the grant date. Read SEC document |
| May 08, 2020 Filed May 12, 2020 20:35 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantRestricted Stock Units · Derivative | 1,077.229 | $0.00 | $0.00 |
DisclosureSEC source: 0000911916-20-000104 · edgar.xml · derivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,917.81 Underlying: Common Stock · 1,077.229 shares Expires not disclosed F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F5 · derivative.exercise_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. F5 · derivative.expiration_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. F6 · balance_after: Includes Restricted Stock Units granted in prior years that are subject to different mandatory deferral periods. Read SEC document |
| May 08, 2020 Filed May 12, 2020 20:35 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 500 | $0.00 Strike: $120.68 | $0.00 |
DisclosureSEC source: 0000911916-20-000104 · edgar.xml · derivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,096.737 Underlying: Common Stock · 500 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: The units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: The units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 48.192 phantom stock units accrued on April 30, 2020 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| May 07, 2020 Filed May 8, 2020 21:58 UTC | ECOLAB INC. ECL · Entity 2954 | GrantNon-Employee Director Stock Option (Right to Buy) · Derivative | 1,417 | $0.00 Strike: $195.26 | $0.00 |
DisclosureSEC source: 0001179110-20-005645 · edgar.xml · derivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,417 Underlying: Common Stock · 1,417 shares Expires 2030-05-07 F1 · derivative.exercise_date: The option will become exercisable, on a cumulative basis, as to 25% of the option shares (excluding any fractional portion less than one share), on the last day of each of the first, second and third three-month periods following its date of grant and as to the remaining shares on the last day of the fourth three-month period following its date of grant; provided, however, that if a Change in Control of the Company (as that term is defined in the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan) will occur, then the option will become immediately exercisable in full. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 21:30 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 189.83 | $158.04 | $30,000.16 |
DisclosureSEC source: 0001179110-20-004546 · edgar.xml · nonDerivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,503.6 F1 · balance_after: Includes 46.17 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 21:30 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 197.74 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-004546 · edgar.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,267.6 Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 21:22 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 328.217 | $0.00 Strike: $99.02 | $0.00 |
DisclosureSEC source: 0000911916-20-000090 · edgar.xml · derivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,548.545 Underlying: Common Stock · 328.217 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F3 · derivative.expiration_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F4 · balance_after: Includes 38.550 phantom stock units accrued on January 31, 2020 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| February 12, 2020 Filed Feb 12, 2020 23:41 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | Exercise / conversionRestricted Stock Units · Derivative | 97,412 | $0.00 | $0.00 |
DisclosureSEC source: 0001005201-20-000012 · wf-form4_158155085976896.xml · derivative · entry 5 HIGGINS ARTHUR J · CIK 0001142083 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,825 Underlying: Common Stock · 97,412 shares Expires 2022-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock. F4 · price: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. F3 · derivative.exercise_date: One-third of these restricted stock units are scheduled to vest on each of February 12, 2020, 2021 and 2022. Read SEC document |
| February 12, 2020 Filed Feb 12, 2020 23:41 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | Tax withholdingCommon Stock | 31,008 | $1.35 | $41,860.80 |
DisclosureSEC source: 0001005201-20-000012 · wf-form4_158155085976896.xml · nonDerivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,739 F1 · shares: Represents shares of common stock withheld for payment of taxes upon the vesting of restricted stock units. Read SEC document |
| February 12, 2020 Filed Feb 12, 2020 23:41 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | Exercise / conversionCommon Stock | 97,412 | $0.00 | $0.00 |
DisclosureSEC source: 0001005201-20-000012 · wf-form4_158155085976896.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,747 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2020 Filed Feb 6, 2020 22:49 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | Exercise / conversionRestricted Stock Units · Derivative | 62,399 | $0.00 | $0.00 |
DisclosureSEC source: 0001005201-20-000006 · wf-form4_158102932713693.xml · derivative · entry 6 HIGGINS ARTHUR J · CIK 0001142083 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,401 Underlying: Common Stock · 62,399 shares Expires 2021-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock. F4 · price: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. F6 · derivative.exercise_date: These restricted stock units are scheduled to vest 33.33% on February 6, 2019, 33.33% on February 6, 2020 and 33.33% on February 6, 2021. Read SEC document |
| February 06, 2020 Filed Feb 6, 2020 22:49 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | Tax withholdingCommon Stock | 21,590 | $1.04 | $22,453.60 |
DisclosureSEC source: 0001005201-20-000006 · wf-form4_158102932713693.xml · nonDerivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,335 F1 · shares: Represents shares of common stock withheld for payment of taxes upon the vesting of restricted stock units. Read SEC document |
| February 06, 2020 Filed Feb 6, 2020 22:49 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | Exercise / conversionCommon Stock | 62,399 | $0.00 | $0.00 |
DisclosureSEC source: 0001005201-20-000006 · wf-form4_158102932713693.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,925 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2020 Filed Feb 6, 2020 22:49 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | GrantRestricted Stock Units · Derivative | 1,037,838 | $0.00 | $0.00 |
DisclosureSEC source: 0001005201-20-000006 · wf-form4_158102932713693.xml · derivative · entry 5 HIGGINS ARTHUR J · CIK 0001142083 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,037,838 Underlying: Common Stock · 1,037,838 shares Expires 2023-02-04 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the registrant's common stock. F4 · price: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. F3 · derivative.exercise_date: One-third of these restricted stock units are scheduled to vest on each of February 4, 2021, 2022 and 2023, assuming continued employment through the applicable vesting date. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 21:57 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 143.18 | $192.06 | $27,499.15 |
DisclosureSEC source: 0001179110-20-000198 · edgar.xml · nonDerivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,069.86 F1 · balance_after: Includes 43.51 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 21:57 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 149.69 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-000198 · edgar.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,883.17 Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 21:44 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 218.121 | $0.00 Strike: $149.00 | $0.00 |
DisclosureSEC source: 0000911916-20-000010 · edgar.xml · derivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,181.778 Underlying: Common Stock · 218.121 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F3 · derivative.expiration_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F4 · balance_after: Includes 41.697 phantom stock units accrued on October 31, 2019 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 01, 2019 Filed Dec 2, 2019 22:20 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | Exercise / conversionRestricted Stock Units · Derivative | 34,860 | $0.00 | $0.00 |
DisclosureSEC source: 0001005201-19-000130 · wf-form4_157532520765635.xml · derivative · entry 5 HIGGINS ARTHUR J · CIK 0001142083 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,860 Underlying: Common Stock · 34,860 shares Expires 2020-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock. F4 · price: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. F3 · derivative.exercise_date: These restricted stock units are scheduled to vest 25% on December 1, 2017, 25% on December 1, 2018, 25% on December 1, 2019 and 25% on December 1, 2020. Read SEC document |
| December 01, 2019 Filed Dec 2, 2019 22:20 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | Tax withholdingCommon Stock | 10,213 | $0.76 | $7,761.88 |
DisclosureSEC source: 0001005201-19-000130 · wf-form4_157532520765635.xml · nonDerivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,526 F1 · shares: Represents shares of common stock withheld for payment of taxes upon the vesting of restricted stock units. Read SEC document |
| December 01, 2019 Filed Dec 2, 2019 22:20 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | Exercise / conversionCommon Stock | 34,860 | $0.00 | $0.00 |
DisclosureSEC source: 0001005201-19-000130 · wf-form4_157532520765635.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,739 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2019 Filed Nov 12, 2019 21:36 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | PurchaseCommon Stock | 25,000 | $0.73 | $18,250.00 |
DisclosureSEC source: 0001005201-19-000125 · wf-form4_157359455355406.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,879 Read SEC document |
| September 30, 2019 Filed Oct 3, 2019 01:24 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 138.66 | $198.33 | $27,499.74 |
DisclosureSEC source: 0001104659-19-052816 · a4.xml · nonDerivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,733.48 F1 · balance_after: Includes 41.85 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan. Read SEC document |
| September 30, 2019 Filed Oct 3, 2019 01:24 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 144.96 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-052816 · a4.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,552.97 Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 20:36 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 202.013 | $0.00 Strike: $136.13 | $0.00 |
DisclosureSEC source: 0000911916-19-000173 · edgar.xml · derivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,921.96 Underlying: Common Stock · 202.013 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F3 · derivative.expiration_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F4 · balance_after: Includes 41.653 phantom stock units accrued on July 31, 2019 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| August 19, 2019 Filed Aug 20, 2019 20:08 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | PurchaseCommon Stock | 25,000 | $1.61 | $40,242.50 |
DisclosureSEC source: 0001005201-19-000103 · wf-form4_156633167517814.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 175,000 Read SEC document |
| August 12, 2019 Filed Aug 12, 2019 22:43 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | PurchaseCommon Stock | 50,000 | $1.54 | $76,900.00 |
DisclosureSEC source: 0001005201-19-000096 · wf-form4_156564976547238.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 150,000 Read SEC document |
| June 30, 2019 Filed Jul 2, 2019 21:03 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 141.16 | $194.81 | $27,499.66 |
DisclosureSEC source: 0001179110-19-008403 · edgar.xml · nonDerivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,408.01 F1 · balance_after: Includes 44.38 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan. Read SEC document |
| June 30, 2019 Filed Jul 2, 2019 21:03 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 147.58 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-008403 · edgar.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,222.47 Read SEC document |
| June 30, 2019 Filed Jul 2, 2019 20:16 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 236.397 | $0.00 Strike: $116.33 | $0.00 |
DisclosureSEC source: 0000911916-19-000143 · edgar.xml · derivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,678.294 Underlying: Common Stock · 236.397 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F3 · derivative.expiration_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. Read SEC document |
| May 10, 2019 Filed May 14, 2019 21:25 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantRestricted Stock Units · Derivative | 1,078.122 | $0.00 | $0.00 |
DisclosureSEC source: 0000911916-19-000114 · edgar.xml · derivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,840.581 Underlying: Common Stock · 1,078.122 shares Expires not disclosed F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F5 · derivative.exercise_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. F5 · derivative.expiration_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination of service as a Director or (2) the date that is three years after the grant date. F6 · balance_after: Includes Restricted Stock Units granted in prior years that are subject to different mandatory deferral periods. Read SEC document |
| May 10, 2019 Filed May 14, 2019 21:25 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 500 | $0.00 Strike: $120.58 | $0.00 |
DisclosureSEC source: 0000911916-19-000114 · edgar.xml · derivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,441.897 Underlying: Common Stock · 500 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. ("Company") Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: The units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: The units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 44.659 phantom stock units accrued on April 30, 2019 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| May 02, 2019 Filed May 3, 2019 21:08 UTC | ECOLAB INC. ECL · Entity 2954 | GrantNon-Employee Director Stock Option (Right to Buy) · Derivative | 1,281 | $0.00 Strike: $182.98 | $0.00 |
DisclosureSEC source: 0001179110-19-005560 · edgar.xml · derivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,281 Underlying: Common Stock · 1,281 shares Expires 2029-05-02 F1 · derivative.exercise_date: The option will become exercisable, on a cumulative basis, as to 25% of the option shares (excluding any fractional portion less than one share), on the last day of each of the first, second and third three-month periods following its date of grant and as to the remaining shares on the last day of the fourth three-month period following its date of grant; provided, however, that if a Change in Control of the Company (as that term is defined in the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan) will occur, then the option will become immediately exercisable in full. Read SEC document |
| March 31, 2019 Filed Apr 2, 2019 21:44 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 156.23 | $176.03 | $27,500.39 |
DisclosureSEC source: 0001179110-19-004564 · edgar.xml · nonDerivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,074.89 F1 · balance_after: Includes 53.44 shares acquired pursuant to a dividend reinvestment feature of the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan. Read SEC document |
| March 31, 2019 Filed Apr 2, 2019 21:44 UTC | ECOLAB INC. ECL · Entity 2954 | GrantCommon Stock | 163.33 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-004564 · edgar.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,865.22 Read SEC document |
| March 31, 2019 Filed Apr 2, 2019 23:04 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 216.144 | $0.00 Strike: $127.23 | $0.00 |
DisclosureSEC source: 0000911916-19-000101 · edgar.xml · derivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,897.238 Underlying: Common Stock · 216.144 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F3 · derivative.expiration_date: Units are to be settled in cash in ten annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs. F4 · balance_after: Includes 49.345 phantom stock units accrued on January 31, 2019 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 14, 2019 Filed Mar 18, 2019 12:02 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | PurchaseCommon Stock | 10,000 | $4.17 | $41,700.00 |
DisclosureSEC source: 0001005201-19-000046 · wf-form4_155291053503733.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 100,000 Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 11:03 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | PurchaseCommon Stock | 500 | $123.28 | $61,637.65 |
DisclosureSEC source: 0000911916-19-000036 · edgar.xml · nonDerivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,400 Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:21 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | GrantPerformance Shares · Derivative | 38,064 | $0.00 | $0.00 |
DisclosureSEC source: 0001005201-19-000023 · wf-form4_155017925472007.xml · derivative · entry 2 HIGGINS ARTHUR J · CIK 0001142083 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,064 Underlying: Common Stock · 38,064 shares Expires not disclosed F4 · derivative.exercise_price: Represents the current tranche of performance shares earned under the 2018 performance share award as of February 12, 2019, at which date the Compensation Committee certified the extent to which the current tranche performance criteria were achieved. Each earned performance share represents the contingent right to receive one share of common stock. F3 · price: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. F5 · derivative.exercise_date: Each performance share will convert into one share of common stock upon vesting and settlement in the first quarter of 2021. F5 · derivative.expiration_date: Each performance share will convert into one share of common stock upon vesting and settlement in the first quarter of 2021. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 21:21 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | GrantRestricted Stock Units · Derivative | 292,237 | $0.00 | $0.00 |
DisclosureSEC source: 0001005201-19-000023 · wf-form4_155017925472007.xml · derivative · entry 1 HIGGINS ARTHUR J · CIK 0001142083 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,237 Underlying: Common Stock · 292,237 shares Expires 2022-02-12 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the registrant's common stock. F3 · price: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. F2 · derivative.exercise_date: One-third of these restricted stock units are scheduled to vest on each of February 12, 2020, 2021 and 2022, assuming continued employment through the applicable vesting date. Read SEC document |
| February 06, 2019 Filed Feb 7, 2019 21:07 UTC | Assertio Therapeutics, Inc ASRT · Entity 149352 | Exercise / conversionRestricted Stock Units · Derivative | 62,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001005201-19-000006 · wf-form4_154957363092978.xml · derivative · entry 5 HIGGINS ARTHUR J · CIK 0001142083 · Director · Director, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,800 Underlying: Common Stock · 62,400 shares Expires 2021-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock. This transaction represents the settlement of vested restricted stock units in shares of common stock. F4 · price: The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities. F3 · derivative.exercise_date: These restricted stock units are scheduled to vest 33.33% on February 6, 2019, 33.33% on February 6, 2020 and 33.33% on February 6, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.